Belinda Whitlock, 55, experienced severe fatigue, nausea, and stomach pain, which were initially misdiagnosed as menopause symptoms. Despite being prescribed Hormone Replacement Therapy (HRT), her health did not improve. A subsequent ultrasound, prompted by HRT-induced vaginal bleeding, unexpectedly revealed signs of a fatty liver. Further tests confirmed she had advanced liver fibrosis, a condition where scarring builds up in the liver, impeding its function. This condition, affecting up to one in five adults, is caused by long-term inflammation from fatty liver disease, often linked to obesity.

Belinda, a mother-of-four, recalled the diagnosis as a 'sledgehammer blow,' particularly as her mother had died of liver cancer at 46. Fearing a similar fate, she made significant lifestyle changes, adopting a Mediterranean diet, incorporating daily coffee, and eliminating takeaways. After seven months, she had lost two stone, but scans showed little improvement in her liver. With a Body Mass Index (BMI) of 45, indicating severe obesity, she sought alternative solutions.

Currently, no drugs are licensed in the UK specifically to treat liver disease. However, after learning about the potential of GLP-1 weight-loss drugs, Belinda began a private prescription in August, costing hundreds of pounds monthly. Since then, she has lost an additional five stone, reducing her BMI to 31. Remarkably, recent scans indicate her liver fibrosis is reversing, offering her renewed hope.

Experts are increasingly recognizing GLP-1 drugs, such as Mounjaro, as a crucial tool in combating liver disease. Professor Philip Newsome, a liver expert at King's College London, highlights the alarming rise in liver disease cases, largely driven by poor diets and sedentary lifestyles. He emphasizes the promising research demonstrating these drugs can help reverse liver damage, a feat previously considered impossible. The British Liver Trust estimates that 80 percent of individuals with fatty liver disease remain undiagnosed in its early, often asymptomatic, stages.

Liver disease progresses through four stages, beginning with excess fat, leading to inflammation, and eventually scarring. Untreated, it can advance to end-stage liver disease, or cirrhosis, which is typically irreversible without a transplant. In this advanced stage, the liver fails to filter toxins, leading to symptoms like jaundice, fatigue, abdominal pain, itching, and swelling. Professor Newsome notes that while cirrhosis may not fully reverse, treating the underlying cause can lead to significant remodeling of scar tissue, moving the liver to a much less harmful state.

Belinda's success is not isolated. Gillian Scott, 57, a civil servant diagnosed with cirrhosis in 2023 due to long-standing type 2 diabetes and obesity, also found relief with Mounjaro. After switching to the drug in June 2024, she lost nine stone, and scans showed her condition improved from cirrhosis to the less severe stage of fibrosis.

A growing body of research supports these findings. A 2024 study published in the New England Journal Of Medicine reported that 62 percent of patients on the highest dose of Mounjaro (15mg) experienced complete resolution of fatty liver disease and normalized liver function. Professor Newsome suggests these drugs offer benefits beyond weight loss and blood-sugar control, with evidence indicating a direct effect of the GLP-1 component on immune cells in the liver.

Despite compelling evidence and their approval in the US and Europe, GLP-1 drugs are not yet approved on the NHS for liver disease in the UK, with a decision expected this summer. For patients like Belinda, this delay comes at a substantial financial cost. She has dipped into her pension and sought family assistance to afford the life-saving medication, underscoring the urgent need for the NHS to recognize and adopt these beneficial treatments.